IKZF1 or CDKN2A/B deletions were demonstrated to be adverse prognostic factors for Ph+ ALL patients in several studies [36–39], and there were evidences that these might not be overcome by allo-HSCT [35, 40]. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.